Has Marnin Fischbach received payments from drug or device companies?

Yes. Drug and device makers reported $3,513 in general payments to Marnin Fischbach across 162 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Marnin Fischbach did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Marnin Fischbach come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Marnin Fischbach

Psychiatry · Seven Fields, PANPI 1043290521

Payments from drug & device makers

$3,513in general payments, 2019–2025

Across 162 payments — averaging $21.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Takeda Pharmaceuticals U.S.A., Inc.$891
AbbVie$658
Otsuka America Pharmaceutical, Inc.$479
Neos Therapeutics, LP$374
Ironshore Pharmaceuticals Inc.$270
Neurocrine Biosciences, Inc.$269
plus $573 from 10 others

What the payments were for

Food & beverage$3,512100%
Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Takeda Pharmaceuticals U.S.A., Inc.	37	$891
AbbVie(2 entities)	44	$658
Otsuka America Pharmaceutical, Inc.	18	$479
Neos Therapeutics, LP	19	$374
Ironshore Pharmaceuticals Inc.	4	$270
Neurocrine Biosciences, Inc.	13	$269
Lundbeck LLC	11	$198
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	2	$97
Alkermes, Inc.	4	$94
Corium, LLC	2	$52
Tris Pharma Inc	2	$36
Bausch Health US, LLC	2	$30
Neuronetics, Inc.	1	$21
Vanda Pharmaceuticals Inc.	1	$18
Sunovion Pharmaceuticals Inc.	1	$15
Aytu Biopharma, Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Jornay PM 20mg capsules (Bottle of 100)$152
REXULTI$123

How this compares

$3,513 in reported general payments places this provider in the 85th percentile of 1,838 psychiatry providers in Pennsylvania.

See all psychiatry providers in Pennsylvania →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
FetzimaLevomilnacipran Hcl	11	$5,158
LamictalLamotrigine	11	$3,801
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine	15	$661
Bupropion XlBupropion Hcl	27	$468
Sertraline Hcl	59	$309
Gabapentin	29	$264
Bupropion Hcl SrBupropion Hcl	35	$250
Lamotrigine	46	$227
Trazodone Hcl	17	$225
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine	17	$206
Buspirone Hcl	33	$153
Clonazepam	40	$137
Nortriptyline Hcl	13	$126
Olanzapine	19	$109
Escitalopram Oxalate	16	$89

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AbbVieFetzima	$658	$5,15811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,838 psychiatry providers in Pennsylvania.

Other psychiatry in Seven Fields

Michelle BarwellSeven Fields$22K
Cherian VergheseNorristown$16.3M
Steven ArnoldPhiladelphia$4.1M
Paul GrossAllentown$4.1M
Shivkumar HattiMedia$4M
Rebecca RomaPittsburgh$3.3M
Matthew BergerMoosic$2.4M
Michael ThasePhiladelphia$2.2M
Robert NelsonWyomissing$2.2M
Mark MattaNew Castle$847K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →